mRNA/Biomarker RNA Biodistribution Analysis

A messenger RNA (mRNA) can encode a protein leading to desired biological functions, supporting the rationale for developing mRNA-based therapeutics. Creative Bioarray offers the RNA ISH assay to visualize and monitor the delivery and biodistribution of these synthetic mRNA molecules to access the specificity and efficacy of these therapies. Our mRNA/Biomarker RNA Biodistribution Analysis services can help you validate and accelerate your gene therapy development.

Figure 1. Lack of detection of COVID mRNA vaccine via in situ hybridization in human placental explants. Chorionic villi explants derived from second (n = 2) or third trimester (n = 2) human placentas were incubated with 0.1 mg/mL (not shown) or 1 mg/mL mRNA-1237 or BNT162B2 vaccines. After 0.5 h or 4 h, tissues were fixed, paraffin embedded, sectioned and probed for mRNA vaccine using RNA in situ hybridization (A and B) Positive and (B) negative controls for RNA ISH detection of mRNA vaccine. Peptidylprolyl isomerase B (PPIB) was used as a positive control. Pink dots corresponding to PPIB mRNA can be observed within the chorionic villi at 20X and 40X. DapB was used as a negative control. No signal was detected at 20 or 40X. (C) In situ detection of mRNA vaccine in vaccine-exposed explants. No signal was evident in explants incubated with either vaccine at any of the two time points.

RNA In Situ Hybridization (RNA ISH) assay is a valuable technique in mRNA and Biomarker RNA Biodistribution analysis, especially in the context of RNA vaccine development. Here are some of its advantages and applications:

• Spatial Resolution: RNA FISH provides exceptional spatial resolution at the single-cell level. This allows the visualization and localization of specific mRNA molecules in the intracellular context.
• Quantitative Analysis: It allows quantitative analysis of gene expression in individual cells.
• Simultaneous Detection: Using multiple fluorescent probes, simultaneous detection of different mRNAs can be conducted, which is highly applicable in biomarker research and understanding the interaction of multiple genes in response to the vaccine.
• Insight into Cellular Mechanisms: RNA FISH can give valuable insights into cellular processes and mechanisms, such as transcription and translation, vital for understanding the vaccine's performance and response.
• Biodistribution Analysis: Another important application in vaccine development is biodistribution analysis. By applying RNA FISH to tissue samples, it is possible to map out the sites of mRNA delivery, localization, and expression, thereby understanding the effect and reach of the vaccine.
• Safety and Efficacy Studies: RNA FISH can help evaluate the safety and efficacy of RNA vaccines by enabling the monitoring of the temporal and spatial expression of the vaccine-induced mRNA and the immunological responses at cellular levels.

Through these applications, RNA FISH constitutes an effective tool for mRNA/Biomarker RNA Biodistribution analysis in the process of RNA vaccine development, contributing to both the fundamental mechanistic understanding and translational success of these vaccines.

The field of mRNA vaccines has seen exponential growth in recent times, largely due to the swift approval and widespread distribution of mRNA vaccines targeting COVID-19, which carry the gene for the virus's spike protein. These vaccines are delivered as lipid nanoparticles (LNPs), and their acceptance in clinical settings paves the way for novel therapeutic applications across a multitude of diseases.

Features of mRNA/Biomarker RNA Biodistribution Analysis

(1) Detect and identify cellular subtypes
(2) Synthetic RNA molecule biomarker analysis
(3) Custom probes designed within 1-2 weeks
(4) Fastest turnaround time

Benefits of mRNA/Biomarker RNA Biodistribution Analysis

(1) Detect and identify cellular subtypes
(2) Visualize gene regulation with morphological context
(3) Validate miRNA biomarkers in intact tissues
(4) Assess small RNA therapeutic delivery mechanism
(5) Evaluate biodistribution and efficacy of therapy
(6) Add a visual dimension to heterogeneous tissue biology and analysis

Creative Bioarray offers mRNA/Biomarker RNA Biodistribution Analysis for you as follows:

• Probe design
• Probe synthesis
• ISH staining
• Imaging
• Data analysis

Quotation and ordering

Our customer service representatives are available 24hr a day! We thank you for considering Creative Bioarray as your mRNA/Biomarker RNA Biodistribution Analysis partner.

References

1. Sahin, U., Karikó, K. & Türeci, Ö. mRNA-based therapeutics — developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759–780 (2014).
2. Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines — a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).
3. Hajj, K. A. & Whitehead, K. A. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat. Rev. Mater. 2, 17056 (2017).
4. Xiong, Q., Lee, G. Y., Ding, J., Li, W. & Shi, J. Biomedical applications of mRNA nanomedicine. Nano Res. 11, 5281–5309 (2018).
5. Li, B., Zhang, X. & Dong, Y. Nanoscale platforms for messenger RNA delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 11, e1530 (2019).
6. Meng, C., Chen, Z., Li, G., Welte, T. & Shen, H. Nanoplatforms for mRNA therapeutics. Adv. Ther. 4, 2000099 (2021).
7. Kim, J., Eygeris, Y., Gupta, M. & Sahay, G. Self-assembled mRNA vaccines. Adv. Drug Deliv. Rev. 170, 83–112 (2021).
8. Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
9. Anderson, E. J. et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N. Engl. J. Med. 383, 2427–2438 (2020).